| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Neuropsychiatry*
and
Microbiology,
Sapporo Medical University,
Sapporo, the Second Department of Medicine,
Hokkaido University, Sapporo, the Kansai College of Oriental
Medicine,§ Osaka, Japan, and the Department
of Neuropsychiatry,¶ Tokyo University,
Tokyo, Japan, and Laboratory of Central Nervous System
Studies,||
National Institute of Neurological Disorders
and Stroke, National Institutes of Health, Bethesda, Maryland
Advanced glycation end products (AGEs) have been implicated in the chronic complications of diabetes mellitus and have been reported to play an important role in the pathogenesis of Alzheimer's disease. In this study, we examined the immunohistochemical localization of AGEs, amyloid ß protein (Aß), apolipoprotein E (ApoE), and tau protein in senile plaques, neurofibrillary tangles (NFTs), and cerebral amyloid angiopathy (CAA) in Alzheimer's disease and other neurodegenerative diseases (progressive supranuclear palsy, Pick's disease, and Guamanian amyotrophic lateral sclerosis/Parkinsonism-dementia complex). In most senile plaques (including diffuse plaques) and CAA from Alzheimer's brains, AGE and ApoE were observed together. However, approximately 5% of plaques were AGE positive but Aß negative, and the vessels without CAA often showed AGE immunoreactivity. In Alzheimer's disease, AGEs were mainly present in intracellular NFTs, whereas ApoE was mainly present in extracellular NFTs. Pick's bodies in Pick's disease and granulovacuolar degeneration in various neurodegenerative diseases were also AGE positive. In non-Alzheimer neurodegenerative diseases, senile plaques and NFTs showed similar findings to those in Alzheimer's disease. These results suggest that AGE may contribute to eventual neuronal dysfunction and death as an important factor in the progression of various neurodegenerative diseases, including Alzheimer's disease.
This article has been cited by other articles:
 |
|
 |
|
  F. Irie, A. L. Fitzpatrick, O. L. Lopez, L. H. Kuller, R. Peila, A. B. Newman, and L. J. Launer Enhanced Risk for Alzheimer Disease in Persons With Type 2 Diabetes and APOE {varepsilon}4: The Cardiovascular Health Study Cognition Study Arch Neurol, January 1, 2008; 65(1): 89 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Scheele, A. R. Nielsen, T. B. Walden, D. A. Sewell, C. P. Fischer, R. J. Brogan, N. Petrovic, O. Larsson, P. A. Tesch, K. Wennmalm, et al. Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration? FASEB J, November 1, 2007; 21(13): 3653 - 3665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Luchsinger, C. Reitz, B. Patel, M.-X. Tang, J. J. Manly, and R. Mayeux Relation of Diabetes to Mild Cognitive Impairment Arch Neurol, April 1, 2007; 64(4): 570 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kuhla, C. Haase, K. Flach, H.-J. Luth, T. Arendt, and G. Munch Effect of Pseudophosphorylation and Cross-linking by Lipid Peroxidation and Advanced Glycation End Product Precursors on Tau Aggregation and Filament Formation J. Biol. Chem., March 9, 2007; 282(10): 6984 - 6991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Arvanitakis, J. A. Schneider, R. S. Wilson, Y. Li, S. E. Arnold, Z. Wang, and D. A. Bennett Diabetes is related to cerebral infarction but not to AD pathology in older persons Neurology, December 12, 2006; 67(11): 1960 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Akomolafe, A. Beiser, J. B. Meigs, R. Au, R. C. Green, L. A. Farrer, P. A. Wolf, and S. Seshadri Diabetes Mellitus and Risk of Developing Alzheimer Disease: Results From the Framingham Study Arch Neurol, November 1, 2006; 63(11): 1551 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hernebring, G. Brolen, H. Aguilaniu, H. Semb, and T. Nystrom Elimination of damaged proteins during differentiation of embryonic stem cells PNAS, May 16, 2006; 103(20): 7700 - 7705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sato, N. Shimogaito, X. Wu, S. Kikuchi, S.-i. Yamagishi, and M. Takeuchi Toxic Advanced Glycation End Products (TAGE) Theory in Alzheimer's Disease American Journal of Alzheimer's Disease and Other Dementias, May 1, 2006; 21(3): 197 - 208. [Abstract] [PDF]
|
|
|
|
 |
|
 B. KUHLA, H.-J. LUTH, D. HAFERBURG, K. BOECK, T. ARENDT, and G. MUNCH Methylglyoxal, Glyoxal, and Their Detoxification in Alzheimer's Disease Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 211 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Luth, V. Ogunlade, B. Kuhla, R. Kientsch-Engel, P. Stahl, J. Webster, T. Arendt, and G. Munch Age- and Stage-dependent Accumulation of Advanced Glycation End Products in Intracellular Deposits in Normal and Alzheimer's Disease Brains Cereb Cortex, February 1, 2005; 15(2): 211 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Blair, A. R. Folsom, D. S. Knopman, M. S. Bray, T. H. Mosley, E. Boerwinkle, and for the Atherosclerosis Risk in Communities Study APOE genotype and cognitive decline in a middle-aged cohort Neurology, January 25, 2005; 64(2): 268 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schnaider Beeri, U. Goldbourt, J. M. Silverman, S. Noy, J. Schmeidler, R. Ravona-Springer, A. Sverdlick, and M. Davidson Diabetes mellitus in midlife and the risk of dementia three decades later Neurology, November 23, 2004; 63(10): 1902 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Kanaya, E. Barrett-Connor, G. Gildengorin, and K. Yaffe Change in Cognitive Function by Glucose Tolerance Status in Older Adults: A 4-Year Prospective Study of the Rancho Bernardo Study Cohort Arch Intern Med, June 28, 2004; 164(12): 1327 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Chen, M. A. Wollmer, F. Hoerndli, G. Munch, B. Kuhla, E. I. Rogaev, M. Tsolaki, A. Papassotiropoulos, and J. Gotz Role for glyoxalase I in Alzheimer's disease PNAS, May 18, 2004; 101(20): 7687 - 7692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Arvanitakis, R. S. Wilson, J. L. Bienias, D. A. Evans, and D. A. Bennett Diabetes Mellitus and Risk of Alzheimer Disease and Decline in Cognitive Function Arch Neurol, May 1, 2004; 61(5): 661 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Janson, T. Laedtke, J. E. Parisi, P. O'Brien, R. C. Petersen, and P. C. Butler Increased Risk of Type 2 Diabetes in Alzheimer Disease Diabetes, February 1, 2004; 53(2): 474 - 481. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Horiguchi, K. Uryu, B. I. Giasson, H. Ischiropoulos, R. LightFoot, C. Bellmann, C. Richter-Landsberg, V. M.-Y. Lee, and J. Q. Trojanowski Nitration of Tau Protein Is Linked to Neurodegeneration in Tauopathies Am. J. Pathol., September 1, 2003; 163(3): 1021 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Farris, S. Mansourian, Y. Chang, L. Lindsley, E. A. Eckman, M. P. Frosch, C. B. Eckman, R. E. Tanzi, D. J. Selkoe, and S. Guenette Insulin-degrading enzyme regulates the levels of insulin, amyloid beta -protein, and the beta -amyloid precursor protein intracellular domain in vivo PNAS, April 1, 2003; 100(7): 4162 - 4167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. HALLIWELL Hypothesis: Proteasomal Dysfunction: A Primary Event in Neurogeneration that Leads to Nitrative and Oxidative Stress and Subsequent Cell Death Ann. N.Y. Acad. Sci., May 1, 2002; 962(1): 182 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Peila, B. L. Rodriguez, and L. J. Launer Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies: The Honolulu-Asia Aging Study Diabetes, April 1, 2002; 51(4): 1256 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Tawana and D B Ramsden Progressive supranuclear palsy Mol. Pathol., December 1, 2001; 54(6): 427 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Luchsinger, M.-X. Tang, Y. Stern, S. Shea, and R. Mayeux Diabetes Mellitus and Risk of Alzheimer's Disease and Dementia with Stroke in a Multiethnic Cohort Am. J. Epidemiol., October 1, 2001; 154(7): 635 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Singleton, R. Hall, C. G. Ballard, R. H. Perry, J. H. Xuereb, D. C. Rubinsztein, C. Tysoe, P. Matthews, B. Cordell, S. Kumar-Singh, et al. Pathology of early-onset Alzheimer's disease cases bearing the Thr113-114ins presenilin-1 mutation Brain, December 1, 2000; 123(12): 2467 - 2474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Bennett Diabetes and Change in Cognitive Function Arch Intern Med, January 24, 2000; 160(2): 141 - 143. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
